New hope for rare leukemia: drug targets MEK gene in BRAF-Negative patients
NCT ID NCT04322383
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study tests a drug called binimetinib for people with hairy cell leukemia that does not have the common BRAF gene mutation. The drug targets a different gene, MEK, which is often altered in these patients. The goal is to see if it can shrink or control the cancer in 40 adults whose disease has returned or not responded to prior treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo therapy targets rare blood cancer in early trial